MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
CRISPR Therapeutics AG Net Income 2011-2026 | CRSP
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income CRISPR Therapeutics AG
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -366 M | -154 M | -650 M | 378 M | -349 M | 66.9 M | -165 M | -68.4 M | -23.2 M | -25.8 M | -6.8 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 378 M | -650 M | -124 M |
Quarterly Net Income CRISPR Therapeutics AG
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -106 M | -209 M | -136 M | - | -85.9 M | -126 M | -117 M | - | -112 M | -77.7 M | -53.1 M | - | -175 M | -186 M | -179 M | - | -127 M | 759 M | -113 M | -107 M | -92.4 M | -79.7 M | -69.7 M | 30.5 M | 138 M | -53.7 M | -48.4 M | -47.6 M | -50.7 M | -38.4 M | -28.3 M | 140 K | -24.7 M | -22.3 M | -21.5 M | 17.1 M | -14.7 M | -17.2 M | -8.44 M | -12.3 M | -6.35 M | -3.64 M | -3.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 759 M | -209 M | -41.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
-33.4 M | $ 2.9 | 4.69 % | $ 163 M |  China |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-208 M | - | - | $ 1.01 B | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.24 | -4.14 % | $ 7.8 B |  Australia |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Aptose Biosciences
APTO
|
-25.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.57 | -1.91 % | $ 16.1 M | USA |
 |
Brickell Biotech
BBI
|
-5.69 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 116.68 | 0.45 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 223.43 | 0.44 % | $ 5 B |  Danmark |
 |
Athira Pharma
ATHA
|
-96.9 M | - | - | $ 269 M | USA |
 |
Atreca
BCEL
|
-97.2 M | - | -11.76 % | $ 5.79 M | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 9.61 | 1.37 % | $ 1.52 B | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.88 M | $ 4.19 | -5.42 % | $ 9.12 B |  Israel |
 |
Beam Therapeutics
BEAM
|
-377 M | $ 29.29 | 0.91 % | $ 2.41 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 M | $ 69.61 | 6.15 % | $ 9.31 B | USA |
 |
Biogen
BIIB
|
1.63 B | $ 176.68 | 1.06 % | $ 25.7 B | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-25 M | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-114 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
-98 M | - | -7.31 % | $ 87 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-73.9 M | $ 14.11 | 1.11 % | $ 4.36 B | USA |
 |
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-19.8 M | - | -74.18 % | $ 955 K | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Baudax Bio
BXRX
|
-58.8 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
BioLineRx Ltd.
BLRX
|
-27.1 M | $ 3.06 | 1.66 % | $ 908 M | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
115 M | $ 92.72 | -0.54 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
-616 M | - | -6.81 % | $ 3.04 B | USA |